1. Introduction
===============

Amniotic membrane exhibits anti-inflammatory, anti-bacterial, anti-fibrosis, anti-scarring, analgesic effects, and promotes epithelialization. It has been used as a wound dressing for many years for burns, diabetic foot ulcers, fistulas, and venous leg ulcers.^\[[@R1],[@R2]\]^ Amniotic membrane is also applied to ocular surface tissue repair in ophthalmology. It is used in glaucoma surgery to inhibit tissue scar formation and provide a mechanical barrier.^\[[@R3]\]^ Amniotic membrane cannot only be used as a substitute for oral mucosa,^\[[@R4]\]^ but also a good carrier for in vitro cell culture.^\[[@R5]\]^ However, the application of amniotic membrane is limited as it requires suturing during surgery. It is fragile and firmly adheres to the wound. It may cause bleeding and pain when changing the bandage.^\[[@R1]\]^ At the same time, the amniotic membrane will be gradually dissolved in human tissue. For example, in glaucoma surgery, the amniotic membrane will be dissolved in the sclera about 2 weeks after surgery,^\[[@R6]\]^ and the amniotic tissue will be maintained in the ocular surface covering operation for about 2 weeks and then dissolved.^\[[@R7],[@R8]\]^ Therefore, Wollensak et al believe that biomechanical improvement can improve the clinical application and expand the application range of the amniotic membrane.^\[[@R9]\]^

Wollensak et al first used UVA/riboflavin cross-linking to treat keratoconus in 2003.^\[[@R10]\]^ Cross-linking refers to the establishment of chemical bonds between molecules through chemical reactions. Cross-linking can change the connection between collagen fibers.^\[[@R11]\]^ In the UVA/riboflavin corneal cross-linking process, riboflavin releases oxygen monomer, which induces cross-linking between corneal collagen fibers. The collagen cross-linking is associated with the vulnerability of collagen-containing tissues,^\[[@R12],[@R13]\]^ and the amnion contains laminin, proteoglycan, fibronectin, and collagen of type I, III, IV, V, and VII.^\[[@R14]\]^ Therefore, we tried UVA/riboflavin cross-linking (CXL) on the amniotic membrane, observed the changes in biomechanics before and after cross-linking, and examined the ultrastructural changes of the amniotic membrane after cross-linking by transmission electron microscopy.

2. Materials and methods
========================

2.1. Preparation of amniotic membrane tissue
--------------------------------------------

Placenta was obtained from a cesarean section of healthy pregnant women with negative HbsAg, HIV, HBV, BCV, and syphilis tests. The material was taken under aseptic conditions, and the removed amniotic membrane was rinsed with physiological saline and immersed in saline containing gentamicin (40 μ/mL) and amphotericin (2.5 mg/L) for 15 min. The amniotic membrane was cut into 1 cm × 1 cm pieces in size, placed in corneal preservation solution and stored in a 4°C refrigerator. Written informed consent was obtained from all participants, and the study followed the Tenets of the Declaration of Helsinki.

2.2. Grouping
-------------

The fresh amniotic membrane samples in this experiment were divided into three groups: cross-linking group (CX Group), riboflavin group (B2 Group), and the control group (C Group). The samples were processed as follows:
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2.3. Collagen cross-linking of amniotic tissue
----------------------------------------------

The amniotic membrane tissue was completely and adequately soaked for 10 min in 0.1% riboflavin (0.1%; Sigma--Aldrich Inc, St. Louis, MO). A cross-linking system for UV-A illumination (ALL-1; Sunvision Meditech Co. Ltd, China, wavelength 365 nm, irradiance 9 mW/cm^2^, total dose 5.4 J/cm^2^) was used for continuous illumination of 10 min.^\[[@R15]\]^ 0.1% riboflavin solution was applied to keep the amniotic membrane moist during the illumination. The amnion tissue after cross-linking was placed in the corneal preservation solution and stored in a refrigerator at 4°C.

2.4. Mechanical experiment
--------------------------

Thirteen and 11 amniotic membrane tissues were taken from CX group and B2 group, respectively, together with 15 amniotic membrane tissues from C group (the remaining amniotic membrane tissues were used for other studies). Each sample was subjected to a uniaxial tensile test, preloaded (6 cycles) before the experiment, and then subjected to a tensile test until the elongation was 0.01 mm/s. A stress--strain curve was derived and divided into three regions, namely: low stress linear region (AB), nonlinear region (BM), high stress linear region (MN) (Fig. [1](#F1){ref-type="fig"}), from which three mechanical parameters, low-stress elastic modulus (*E*~low~), high-stress region linear modulus (*E*~high~), and tensile strength, were determined.

![Illustration of the stress--strain curve.](medi-99-e20091-g002){#F1}

2.5. Transmission electron microscopy of amniotic membrane
----------------------------------------------------------

Five amniotic membrane tissues were randomly selected from CX Group and B2 Group for electron microscopic imaging and transplantation, respectively.

2.6. Transplantation of amniotic membrane tissue into rabbit\'s conjunctiva and quantification of dissolution and absorption time
---------------------------------------------------------------------------------------------------------------------------------

Eight New Zealand white rabbits (weighing 1.5--2 kg) in group A and B were randomly selected. In group A, the corneal limbus was used as the base of both eyes, and the bulbar conjunctiva was cut 6 mm behind the corneal limbus. The cross-linked amniotic membrane (size 5 mm× 5 mm) was laid flat and implanted under the bulbar conjunctiva, and 10/0 nylon thread was used to suture the bulbar conjunctiva. In group B, the amniotic membrane was immersed in riboflavin solution. Two rabbits in group A and B were sacrificed at 1, 2, 4, and 6 weeks after operation. Eyeballs were taken and fixed with formalin and embedded. Longitudinal sections perpendicular to corneal limbus were made at the center of amniotic membrane transplantation. The dissolution and absorption of amniotic membrane tissue were examined by HE staining.

2.7. Statistics
---------------

All measurement data were expressed as mean ± standard deviation, processed by SPSS l3.0 statistical software package, using independent sample mean *t* test. *P* \< .05 was considered statistically significant.

3. Results
==========

1.  The stress--strain curves of the three groups are shown in Figure [2](#F2){ref-type="fig"}. The mechanical parameters are summarized in Table [1](#T1){ref-type="table"} and Figure 3. The *E*~low~ of the CX Group was 0.6225 ± 0.1724 MPa, which was 1.3 and 1.5 times larger than that of the B2 Group and the C Group, respectively. The *E*~high~ of the CX Group was 16.9081 ± 2.9775 MPa, which was smaller than B2 Group and C Group (0.93 times that of the B2 Group, and 0.79 times that of the C Group). No statistical significance was detected in the tensile strength of the three groups.

2.  After amniotic membrane cross-linking, the collagen fibers showed coarse and bamboo-like changes (Fig. [4](#F4){ref-type="fig"}).

3.  The dissolution of subconjunctival amniotic membrane is shown in Figure [5](#F5){ref-type="fig"}. In Group A, some amniotic membrane tissues were still present under the conjunctiva at 4 weeks, and more inflammatory cells were observed. By the end of 6 weeks, no amniotic membrane tissues and fewer inflammatory cells were observed. In Group B, no obvious amniotic membrane tissue was observed under the conjunctiva at 4 weeks, and fewer inflammatory cells were present.
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###### 

The length, width, and mechanical parameters of the CX group, the B2 group, and the C group.
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![Electron microscopy of the uncross-linked amniotic membrane (A) and the cross-linked amniotic membrane (B). (A) The collagen fibers were smooth and arranged neatly. Magnification: 60,000×. (B) The collagen fibers showed a bamboo-like change, which was coarse and disorderly arranged. Magnification: 60,000×.](medi-99-e20091-g005){#F4}

![(A) a: visible amniotic membrane, many inflammatory cells; b: visible amniotic membrane, fewer inflammatory cells; c: visible amniotic membrane, fewer inflammatory cells; d: visible amniotic membrane, few inflammatory cells; (B) e: visible amniotic membrane, many inflammatory cells; visible amniotic membrane, fewer inflammatory cells; f: invisible amniotic membrane, few inflammatory cells; g: invisible amniotic membrane, no inflammatory cells.](medi-99-e20091-g006){#F5}

4. Discussion
=============

Amniotic membrane has been applied in the treatment of wounds such as burns, diabetic foot ulcers, fistulas, ocular defects, and venous leg ulcers. As a stent, amniotic membrane tissue can delay dissolution and maintain hardness.^\[[@R2]\]^ For example, the amniotic membrane was used under the scleral flap for glaucoma small beam resection to delay the closure of the filtration channel. If the amniotic membrane is of a certain strength and the dissolution rate is reduced, the filtration channel will remain for a longer time.^\[[@R6]\]^ Using the glutaraldehyde (GA) to chemically crosslink the amniotic membrane, Spoerl et al found that the force of the amnion cross-linked with GA at 2.5 mm elongation was significantly increased by 175% versus fresh amnion and 76.8% versus the cryopreserved amnion.^\[[@R16]\]^ Through this cross-linked amniotic tissue, collagenase digestion was almost completely resisted in ocular surface tissue repair. It remained insoluble for up to 90 days and displayed good clinical effects. However, compared with fresh or frozen preservation, the amniotic tissue was dissolved on the 7th day. At present, cross-linking technology is well studied and mainly applied to the cross-linking of the cornea in ophthalmology and used in corneal diseases.^\[[@R17]\]^ Some of the tests have shown that the corneal strength after cross-linking treatment by riboflavin combined with UVA irradiation can be increased by 300%, and the collagen fibers in the anterior corneal matrix are changed to a more compact state, with the tissue hardening effect similar to formaldehyde.^\[[@R18]\]^ CXL can significantly prolong the dissolution time of corneal collagen tissue.^\[[@R19]\]^ The human amniotic membrane was cross-linked with Al~2~(SO~4~)~3~ by Sekar, about 125% increase in the tensile strength was observed in the cross-linked human amniotic membrane compared to human amniotic membrane.^\[[@R20]\]^ Fujisato et al^\[[@R21]\]^ crosslinked amniotic membrane by radiation and chemical methods. Radiation cross-linking with gamma-ray and electron beam and chemical cross-linking with GA were used to investigate the effect of cross-linking on its physicochemical and biodegradation properties. They found that cross-linking took place in the interior of the fiber assembly without impairing the mesh structure, and the cross-linking amniotic membrane was implanted subcutaneously in mice. Also, the dissolution time of amniotic membrane was delayed. Therefore, cross-linking was considered to be an effective approach to reduce the biodegradation rate of amniotic membrane. Lai et al^\[[@R22]\]^ found that when amniotic membrane was treated with glycine, lysine, or glutamic acid, such chemical cross-linking changed the tensile strength and provided a good medium for cell culture. No blood vessels, nerves, or lymphatic vessels are present in the amniotic membrane. It is a flexible tissue with a thickness of about 0.02 to 0.05 mm, divided into an epithelial layer, a basement membrane, a dense layer, a fibroblast layer, and a sponge layer. Like the cornea, the amniotic membrane also contains a large number of collagen fibers. The amniotic basement membrane and the stromal layer contain different collagens, mainly type I, III, IV, V, and VII collagen and fibronectin, laminin, and other components. Amniotic membrane can act as a "transplanted basement membrane" and work as a new healthy, and suitable matrix to promote tissue epithelialization.^\[[@R14]\]^ As amniotic and corneal tissue share certain collagen similarity, the cross-linking technology will also affect the biomechanics and ultrastructure of amnion tissue. Indeed, our research confirmed that the collagen fibers of the amniotic membrane after cross-linking treatment showed a coarse and bamboo-like change. Also, we found that the dissolution time of cross-linked amniotic membrane tissue was prolonged by transplanting the cross-linked amniotic membrane tissue under conjunctiva. The amniotic membrane treated with GA for a longer duration exhibited a greater extent of molecular aggregation, thereby leading to a considerable increase in nanofiber diameter and resistance against collagenase degradation.^\[[@R23]\]^ In this study, we found that after cross-linking treatment, the amniotic membrane underwent biomechanical and ultrastructural changes (Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}); the collagen fibers of amniotic membrane underwent bamboo-like changes (Fig. [4](#F4){ref-type="fig"}); and the biodegradation rate was prolonged (Fig. [5](#F5){ref-type="fig"}). The relationship between the resistance to tissue dissolution and the changes in physical and chemical properties of amniotic membrane after cross-linking needs further study. In addition, we did not study the effect of ultraviolet intensity and irradiation time on the amniotic membrane. In one study, Lai et al used the Blak-Ray high intensity UV lamp (365 nm) to cross-link the riboflavin-treated amniotic membrane, by exposing for different periods of time (i.e., 0--150 min). Results showed that the number of cross-links of amniotic membrane significantly increased with increasing illumination time from 5 to 50 min. However, cross-linking was inhibited by longer irradiation time (i.e., 150 min). Thus, the UV irradiation time may have a profound influence on the fabrication of cross-linked amniotic membrane.^\[[@R24]\]^ Finally, further analysis of ultrastructure could also be one direction of future research. In summary, this study provides experimental data for the biomechanical improvement of amniotic membrane by ultraviolet cross-linking. These findings may improve the clinical efficacy of amniotic membrane tissue application.
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